Princeton Capital Management LLC Has $12.67 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Princeton Capital Management LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 1.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,989 shares of the company’s stock after buying an additional 232 shares during the quarter. Eli Lilly and Company accounts for approximately 4.1% of Princeton Capital Management LLC’s holdings, making the stock its 6th biggest holding. Princeton Capital Management LLC’s holdings in Eli Lilly and Company were worth $12,665,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Everpar Advisors LLC acquired a new position in Eli Lilly and Company during the fourth quarter worth $1,845,000. International Assets Investment Management LLC grew its holdings in shares of Eli Lilly and Company by 5.3% in the 4th quarter. International Assets Investment Management LLC now owns 12,597 shares of the company’s stock worth $7,343,000 after purchasing an additional 632 shares during the last quarter. AMJ Financial Wealth Management acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $201,000. Providence First Trust Co bought a new position in Eli Lilly and Company during the 4th quarter valued at about $274,000. Finally, Aveo Capital Partners LLC lifted its holdings in Eli Lilly and Company by 8.2% during the 4th quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock valued at $1,178,000 after purchasing an additional 153 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insiders Place Their Bets

In related news, major shareholder Lilly Endowment Inc sold 139,490 shares of the stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $852.29, for a total transaction of $118,885,932.10. Following the completion of the transaction, the insider now directly owns 97,869,320 shares of the company’s stock, valued at $83,413,042,742.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 897,283 shares of company stock valued at $805,651,743 in the last three months. 0.13% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Argus raised their price objective on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a report on Tuesday, May 14th. Bank of America lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Jefferies Financial Group increased their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Barclays lifted their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. Finally, Guggenheim increased their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Two research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $961.76.

Eli Lilly and Company Stock Up 2.1 %

Eli Lilly and Company stock opened at $960.02 on Tuesday. The stock has a market capitalization of $912.41 billion, a PE ratio of 141.39, a price-to-earnings-growth ratio of 2.91 and a beta of 0.41. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a twelve month low of $516.57 and a twelve month high of $972.53. The company has a 50 day moving average of $894.03 and a 200-day moving average of $823.97.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. On average, equities research analysts anticipate that Eli Lilly and Company will post 16.51 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 annualized dividend and a yield of 0.54%. Eli Lilly and Company’s payout ratio is currently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.